What's Propelling Ardelyx Incorporated (NASDAQ:ARDX) After Higher Shorts Reported?

Remigio Civitarese
Giugno 19, 2017

According to Zacks, "Ardelyx, Inc.is a clinical-stage biopharmaceutical company".

Several other institutional investors have also recently bought and sold shares of ARDX. Cantor Fitzgerald restated a "buy" rating and issued a $12.00 price objective on shares of Ardelyx in a research report on Wednesday, May 31st. Finally, Vanguard Group Inc. increased its stake in Ardelyx by 4.0% in the first quarter. The firm has a 50-day moving average of $7.47 and a 200 day moving average of $11.88. Citigroup Inc. reaffirmed a "buy" rating and issued a $12.00 target price (down previously from $17.00) on shares of Ardelyx in a research report on Monday, May 15th. Zacks Investment Research upgraded Ardelyx from a "hold" rating to a "buy" rating and set a $6.75 price objective on the stock in a research report on Tuesday, May 23rd.

Teachers Advisors LLC increased its position in Ardelyx Inc (NASDAQ:ARDX) by 45.1% during the fourth quarter, Holdings Channel reports.

WARNING: This article was first published by Sports Perspectives and is the property of of Sports Perspectives. NEA Management Company LLC now owns 14,083,582 shares of the biopharmaceutical company's stock worth $182,242,000 after buying an additional 2,290,951 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Ardelyx by 41.1% in the fourth quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Ardelyx during the fourth quarter valued at about $258,000. Renaissance Technologies LLC now owns 66,300 shares of the biopharmaceutical company's stock worth $941,000 after buying an additional 19,300 shares in the last quarter. Ardelyx has a one year low of $4.05 and a one year high of $16.30. BTIG Research lowered their target price on Ardelyx from $18.00 to $12.00 and set a "buy" rating for the company in a research note on Tuesday, May 23rd. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.06. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of global trademark and copyright laws. Vanguard Group Inc. now owns 1,229,557 shares of the biopharmaceutical company's stock worth $15,554,000 after buying an additional 47,853 shares during the last quarter. Analysts predict that Ardelyx will post ($2.46) EPS for the current fiscal year.

A number of analysts have recently weighed in on the stock. The stock's market capitalization is $206.13 million. The company had a trading volume of 667,078 shares. The company was initiated on Thursday, March 31 by Ladenburg Thalmann.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Friday, May 5th. Rock Springs Capital Management LP now owns 1,975,000 shares of the biopharmaceutical company's stock valued at $25,557,000 after buying an additional 700,000 shares in the last quarter. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/06/16/sphera-funds-management-ltd-buys-193187-shares-of-ardelyx-inc-ardx-updated-updated.html. It operates through the research, development and commercialization of biopharmaceutical products segment. Ardelyx presently has an average rating of Buy and a consensus target price of $14.13.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE